9 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
13 Nov 23
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
8:12am
2023.
An oral presentation delivered by Priya Vakharia, M.D., at the Women in Ophthalmology Summer Symposium in August 2023. The abstract was rated
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
19 May 22
Regulation FD Disclosure
7:43am
, several indications” offers efficiencies in commercial operations RM
Pre-Commercial 2022 & Go-To-Market Strategy 2023 Sources: ASRS; AMA; AAO; Women
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
29 Mar 22
Regulation FD Disclosure
8:25am
-Commercial 2022 & Go-To-Market Strategy 2023 Sources: ASRS; AMA; AAO; Women in Optometry (WO); AOA Excel and Jobson Medical Information; Physician
8-K
EX-99.2
OCUP
Ocuphire Pharma Inc
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
Optometrists 46,000 Total Ophthalmologists 20,000 OcuphireGo-To Market Evaluating commercial sales and distribution partner(s) ASRS; AMA; AAO; Women
DEFA14A
OCUP
Ocuphire Pharma Inc
7 Aug 18
Additional proxy soliciting materials
9:25am
clinical development program is on metastatic triple negative breast cancer (mTNBC). There is nothing currently approved to treat women with mTNBC. To date
424A
80z7mn9kchax
12 Feb 04
Prospectus with significant changes
12:00am
SB-2/A
ukr4 11xchbc
9 Feb 04
Registration of securities for small business issuer (amended)
12:00am
SB-2/A
okw gmr1ai3
6 Jan 04
Registration of securities for small business issuer (amended)
12:00am
SB-2/A
9ih9e
24 Nov 03
Registration of securities for small business issuer (amended)
12:00am
- Prev
- 1
- Next